Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWKSFY)

• Drug Name: GSK3511294 Drug Info
• Synonyms: depemokimab

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 3	[1]
chronic rhinosinusitis with nasal polyps	CA0A	Phase 3	[2]
Eosinophilic granulomatosis with polyangiitis	4A44.A2	Phase 3	[3]
Hypereosinophilic syndrome	2A20.3	Phase 3	[4]

• Cross-matching ID: TTD Drug ID: DMWKSFY

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-5 (IL5)	TTPREZD	IL5_HUMAN	Not Available	[5]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Asthma
• ICD Disease Classification: CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-5 (IL5)	DTT	IL5	6.51E-01	-0.02	-0.11
Interleukin-5 (IL5)	DTT	IL5	1.71E-04	0.12	0.71

References

• [1] ClinicalTrials.gov (NCT05243680) A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05281523) A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05263934) A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy. U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT05334368) A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES). U.S.National Institutes of Health.
• [5] A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.